Three drug programs are racing to succeed tirzepatide, and they are not interchangeable: different mechanisms, different trial results, different corporate stakes. One has already posted the best obesity numbers ever recorded; one disappointed against its own hype; one may win a different organ entirely. The scorecard, on published data only.
The scorecard
| Retatrutide (Lilly) | CagriSema (Novo) | Survodutide (BI/Zealand) | |
|---|---|---|---|
| Mechanism | GIP + GLP-1 + glucagon (triple) | Amylin analog + semaglutide (combo) | Glucagon + GLP-1 (dual) |
| Best published result | -28.3% mean, Phase 3 TRIUMPH-1 (12 mg) | -22.7% at 68 wk, REDEFINE-1 | Mid-to-high teens % at 46 wk, Phase 2 |
| The story | Best numbers in class; unplateaued curves | Solid result that missed Novo's own ~25% guidance | Strongest liver (MASH) data of the three |
| Status | Phase 3 readout positive; submission expected ~2027 | Phase 3 program advanced; filing timeline in flux | Phase 3 ongoing (obesity and MASH) |
| Realistic availability | 2027-2028 | 2026-2027 window discussed | 2027-2028 |
How to read the race
- Pure weight loss: retatrutide leads on published data, and its TRIUMPH-1 readout beat its own Phase 2, the opposite of the usual Phase 3 shrinkage.
- CagriSema's 22.7% is an excellent drug result wearing a disappointing label, because Novo guided the market to ~25%; expectations, not efficacy, wrote those headlines.
- Survodutide's glucagon-forward design targets liver fat directly; if its MASH program delivers, it can win the metabolic-liver indication regardless of the obesity race.
- None are purchasable today, and all three power the same gray market the FDA warns about; 'pipeline' means trials, not telegram vendors.
What this means if you're deciding something now
The practical decision in 2026 is unchanged by the pipeline: tirzepatide and semaglutide are the approved options, and switching costs from an approved 20% to a future 28% are real but not urgent. The pipeline's actual near-term relevance is negotiating leverage and planning: prices across the class will face three-way competition within two years, which is the quiet good news in this table.
Frequently asked questions
Which next-generation weight-loss drug is strongest?
On published trial data, retatrutide: 28.3% mean weight loss in Phase 3, with 45.3% of participants losing 30% or more. CagriSema posted 22.7%; survodutide's Phase 2 sits in the mid-to-high teens with its distinct strength in liver disease.
What is CagriSema and why did it disappoint?
It combines cagrilintide (an amylin analog) with semaglutide. Its 22.7% REDEFINE-1 result would have been historic two years earlier, but Novo had guided expectations near 25%, so a strong result read as a miss.
When will these drugs be available?
Realistic windows: retatrutide and survodutide around 2027-2028 pending submissions and review; CagriSema potentially earlier depending on Novo's filing strategy. Anything sold under these names today is unverifiable gray market.